Study Results from Kansai Medical University Update Understanding of Cerebrovascular Disease (Cardiovascular Safety of Romosozumab Versus Other Anti-Osteoporosis Medications in Patients with Osteoporosis: A Nationwide Health Insurance Claims …): Central Nervous System Diseases and Conditions – Cerebrovascular Disease

2026 JUL 16 (NewsRx) -- By a News Reporter-Staff News Editor at Heart Disease Daily -- Current study results on Central Nervous System Diseases and Conditions - Cerebrovascular Disease have been published. According to news originating from Osaka, Japan, by NewsRx correspondents, research stated, “Romosozumab (Rmab) is a potent anti-osteoporosis agent with dual effects on bone resorption and formation. Although superior to alendronate in fracture reduction, cardiovascular safety concerns have been raised.”

Our news journalists obtained a quote from the research from Kansai Medical University, “This study compared cardiovascular disease (CVD) incidence between Rmab and other anti-osteoporosis medications (AOMs) using Japan’s National Database of Health Insurance Claims. Patients aged 50 years initiating Rmab, parathyroid hormone analogues (PTH), denosumab (Dmab), or bisphosphonates (BP) between March 2019 and March 2023 were identified. Outcomes were acute myocardial infarction, ischemic heart disease, and cerebrovascular disease occurring within 570 days of initiation or within 180 days after discontinuation. Patients with prior myocardial infarction or cerebrovascular disease were excluded. Hazard ratios (HRs) were derived from Cox regression with inverse probability weighting using propensity scores. The study included 25,584 men and 236,467 women receiving Rmab; 50,688 and 289,132 on PTH; 50,319 and 460,182 on Dmab; and 232,484 and 1,144,757 on BP. Cumulative incidence of outcomes was highest with PTH, followed by Dmab, BP, and lowest with Rmab. Compared with PTH, adjusted HRs for Rmab in men were 0.49 for acute myocardial infarction, 0.59 for ischemic heart disease, and 0.70 for cerebrovascular disease. Compared with Dmab, HRs were 0.62, 0.62, and 0.59, respectively. Versus BP, HRs were 0.68, 0.74, and 0.72. All HRs were similarly below 1.0 in women.”

According to the news editors, the research concluded: “After adjustment for baseline characteristics, no excess incidence of cardiovascular events was observed among patients receiving Rmab compared with those receiving other AOMs.”

This research has been peer-reviewed.

For more information on this research see: Cardiovascular Safety of Romosozumab Versus Other Anti-Osteoporosis Medications in Patients with Osteoporosis: A Nationwide Health Insurance Claims Database Study in Japan. Calcified Tissue International, 2026;117(1). Calcified Tissue International can be contacted at: Springer, One New York Plaza, Suite 4600, New York, Ny, United States. (Springer - www.springer.com; Calcified Tissue International - http://www.springerlink.com/content/0171-967x/)

The news correspondents report that additional information may be obtained from Yuki Fujita, Dept. of Hygiene and Public Health, Faculty of Medicine, Kansai Medical University, 2-5-1 Shin-machi, Hirakata, Osaka, 573-1010, Japan. Additional authors for this research include Katsuyasu Kouda, Kenji Fujimori, Nobukazu Okimoto, Shinichi Nakatoh, Junko Tamaki, Shigeyuki Ishii, Sumito Ogawa and Masayuki Iki.

The publisher’s contact information for the journal Calcified Tissue International is: Springer, One New York Plaza, Suite 4600, New York, Ny, United States.

(Our reports deliver fact-based news of research and discoveries from around the world.)